Bausch + Lomb Advances Oral Dry AMD Treatment After Positive FDA Feedback
Event summary
- Bausch + Lomb's BL1243 (tonabersat) oral treatment for dry AMD received constructive FDA feedback on October 6, 2026.
- Initial study design approved in principle; Phase 2 trials expected to start in 2027.
- BL1243 leverages prior clinical experience with tonabersat in 2,100 patients, including a 63-participant DRCR Retina Network study.
- Dry AMD affects the macula, leading to progressive vision loss, with limited current treatment options.
The big picture
Bausch + Lomb's progress with BL1243 reflects the growing focus on developing non-invasive, oral therapies for chronic eye diseases. The FDA's constructive feedback underscores the need for earlier intervention in dry AMD, a condition with limited treatment options. The company's ability to leverage prior clinical data could accelerate development, but success hinges on demonstrating efficacy in a competitive ophthalmology market.
What we're watching
- Clinical Execution
- Whether Bausch + Lomb can successfully navigate the Phase 2 trial timeline and demonstrate efficacy in dry AMD patients.
- Regulatory Pathway
- The pace at which the FDA will review and potentially approve BL1243, given its novel oral administration route.
- Market Differentiation
- How BL1243's convenience and earlier intervention potential will position it against existing and emerging dry AMD treatments.
